These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16884309)

  • 1. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
    Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
    Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
    Ghosh AK; Takayama J; Rao KV; Ratia K; Chaudhuri R; Mulhearn DC; Lee H; Nichols DB; Baliji S; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2010 Jul; 53(13):4968-79. PubMed ID: 20527968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
    Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
    Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
    Ratia K; Pegan S; Takayama J; Sleeman K; Coughlin M; Baliji S; Chaudhuri R; Fu W; Prabhakar BS; Johnson ME; Baker SC; Ghosh AK; Mesecar AD
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16119-24. PubMed ID: 18852458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
    Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
    Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
    Ghosh AK; Takayama J; Aubin Y; Ratia K; Chaudhuri R; Baez Y; Sleeman K; Coughlin M; Nichols DB; Mulhearn DC; Prabhakar BS; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2009 Aug; 52(16):5228-40. PubMed ID: 19645480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
    Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
    J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
    Wen CC; Kuo YH; Jan JT; Liang PH; Wang SY; Liu HG; Lee CK; Chang ST; Kuo CJ; Lee SS; Hou CC; Hsiao PW; Chien SC; Shyur LF; Yang NS
    J Med Chem; 2007 Aug; 50(17):4087-95. PubMed ID: 17663539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
    Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
    Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.
    Zhang L; Lin D; Kusov Y; Nian Y; Ma Q; Wang J; von Brunn A; Leyssen P; Lanko K; Neyts J; de Wilde A; Snijder EJ; Liu H; Hilgenfeld R
    J Med Chem; 2020 May; 63(9):4562-4578. PubMed ID: 32045235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.